Full-Time

Executive Director

Therapeutic Area Operations Leader-Obesity, Muscle, Metabolism

Confirmed live in the last 24 hours

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops medicines for serious diseases

Biotechnology
Healthcare

Compensation Overview

$281.4k - $468.9kAnnually

Senior, Expert

Westchester County, NY, USA + 2 more

More locations: Uxbridge, UK | Berkeley Heights, NJ, USA

Hybrid position requiring 3 days in-office and 2 days from home.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Risk Management
Google Cloud Platform

You match the following Regeneron Pharmaceuticals's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • A Bachelors degree, an advanced degree is highly desirable.
  • 15+ years’ experience of clinical operations experiences in a pharmaceutical or biotech setting with:
  • 10+ years of functional leadership, 10+ years people management, leadership and mentoring experience, 5+ years of leading complex, global clinical trials with outsourced CRO/FSP model(s)
  • Obesity, Muscle, and Metabolism expertise is a must
  • In depth knowledge of GCP and ICH, drug development process, and other relevant guidelines for clinical research activities
  • Experience leading global clinical research activities
  • Exceptional project management, cross-functional team leadership and organizational skills
  • Ability to make decisions, set priorities, and share resources based upon an enterprise mindset, ensuring the benefit to the whole organization. Ability to leverage network to understand the big picture, perspectives, and expertise to maximize performance
  • Ability to provide strategic direction, guidance, and timely decision-making for program teams; ability to capitalize on opportunities and manage risk
  • Ability to anticipate and react to new trends in a competitive landscape and therapeutic areas to guide the organizational strategy
  • Ability to 25% travel
Responsibilities
  • Partner with the Therapeutic Area Head and Global Program Heads, meets regularly to review TA progress and project status
  • Responsible and accountable for the successful operational delivery of all studies in the TA within the Clinical Development Plan (CDP)
  • Contribute functional area expertise to the development of the program and clinical trial operational strategy (e.g., feasibility, timelines, cost estimates) and participates actively at strategy committees (e.g. Development Program Review and Protocol Review)
  • Ensure delivery of quality operational deliverables while ensuring consistency of process and approaches across clinical programs within and across TAs and facilitates streamlined processes across CTM TA Operations leadership
  • Identify and implement opportunities for innovation within clinical trial operations and identifies trends or competitors in disease area landscape to guide operational strategy
  • Liaise closely with the Therapeutic Area Head (TAH), Development Portfolio Management (DPM) and Strategic Program Direction to ensure clinical study deliverables support clinical program goals and project execution
  • Provide consolidated analysis of Key Performance Indicators (KPI) and operational metrics within the assigned TA and developing/managing appropriate action plans
  • Provide input into risk management strategy for clinical study teams and ensuring execution against the risk management plan.
  • Oversee CRO partnership related to delivery of outsourced services, including ensuring that CTM staff provide an appropriate and documented level of oversight for site/CRO/vendor services
  • Actively participate in appropriate governance meetings and acts as representative for CTM in CRO Joint Oversight Committees
  • Interface with senior management to report on milestones including Clinical Operations Review meetings
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops medicines aimed at treating serious diseases such as cancer, eye diseases, and allergic conditions. The company uses its own technologies and extensive research to create new therapies, often collaborating with academic institutions and other pharmaceutical companies to enhance its efforts. This collaboration helps Regeneron stay updated with scientific advancements. Revenue comes from selling approved medicines and licensing technologies, often through partnerships that share development costs and profits. Regeneron works with healthcare providers and regulatory agencies to ensure its products are safe and effective, with the goal of improving patient outcomes.

Company Size

10,001+

Company Stage

IPO

Total Funding

$684M

Headquarters

Town of Greenburgh, New York

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing antibody therapy market offers expansion opportunities for Regeneron.
  • Investment in Truveta's genome project accelerates personalized medicine initiatives.
  • Acquisition of Oxular strengthens Regeneron's position in retinal disorder treatments.

What critics are saying

  • Class action lawsuit may lead to financial liabilities and reputational damage.
  • Truveta investment might not yield expected returns, posing financial risk.
  • Integration challenges with Oxular could affect operational efficiency.

What makes Regeneron Pharmaceuticals unique

  • Regeneron leverages proprietary technologies for innovative therapies in serious diseases.
  • Strategic collaborations enhance Regeneron's research and development capabilities.
  • Regeneron's focus on eye diseases and monoclonal antibodies sets it apart.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Company News

PharmiWeb
Jan 29th, 2025
Antibody Therapy Market To Surge, Expected To Reach Usd 824 Billion By 2033 At A 13.4% Of Cagr

Antibody Therapy MarketThe global antibody therapy market is on a strong growth trajectory, projected to expand at a CAGR of 13.4% from 2023 to 2033. With a valuation of USD 235 billion in 2023, the market is expected to surpass USD 824 billion by the end of the forecast period, driven by advancements in monoclonal antibody therapies and increasing demand for targeted treatments.The growing preference for protein-based, non-chemical treatments has fueled the adoption of monoclonal antibody therapy, particularly for cancer and cell-based diseases. Enhanced research and development efforts, supported by government funding, are further strengthening the effectiveness and accessibility of these treatments. Additionally, the expansion of cancer-specialized hospitals is boosting demand for antibody therapies.The market saw a significant boost during the COVID-19 pandemic, with the FDA approving advanced antibody therapies for treatment, leading to an accelerated CAGR of 18.2% between 2017 and 2022. As immunotherapy and chemotherapy resistance challenges continue, monoclonal antibodies have emerged as a promising alternative due to their high efficacy and reduced side effects.Request a Sample Report Now to get Premium Insights: https://www.futuremarketinsights.com/report-sample#5245502d47422d3134333632Key Takeaways:The antibody therapy market is set to grow from USD 235 billion in 2023 to USD 824 billion by 2033 at a CAGR of 13.4%.Rising cancer prevalence, regulatory approvals, and R&D collaborations are key growth drivers.Monoclonal antibodies offer a promising alternative to traditional chemotherapy, addressing tumor resistance and reducing side effects.Increased demand for targeted therapies and expanded healthcare infrastructure are expected to fuel long-term market growth.Key Growth DriversIncreasing Prevalence of Chronic Diseases The rising incidence of chronic diseases, particularly cancer and autoimmune disorders, is a significant driver for the antibody therapy market. As these conditions become more prevalent, the demand for effective treatment options, such as monoclonal antibodies, increases

PR Newswire
Jan 23rd, 2025
America'S Top 40 High School Scientists To Compete For $1.8 Million In Awards At Prestigious Regeneron Science Talent Search

The Regeneron Science Talent Search Celebrates and Rewards Today's Most Talented Young Minds Driving Innovation and Progress through Scientific ExplorationTARRYTOWN, N.Y. and WASHINGTON, Jan. 23, 2025 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in the 2025 Regeneron Science Talent Search (STS), the U.S.'s longest-running and most distinguished science, technology, engineering and math (STEM) competition for high school seniors

Rome Sentinel
Jan 13th, 2025
ATTENTION NASDAQ: REGN INVESTORS: Contact Berger Montague About a Regeneron Pharmaceuticals, Inc. Class Action Lawsuit

ATTENTION NASDAQ: REGN INVESTORS: contact Berger Montague about a Regeneron pharmaceuticals, inc. class action lawsuit.

GeekWire
Jan 13th, 2025
Truveta secures $320M for genome project

Seattle-based health data company Truveta secured $320 million in funding to launch the Truveta Genome Project, aiming to create the largest and most diverse genomic dataset. The investment, from 17 health systems, Illumina, and Regeneron, elevates Truveta's valuation to over $1 billion. Regeneron will sequence exomes of 10 million volunteers. Truveta's total funding is nearly $500 million, with Microsoft as the exclusive cloud provider for the project.

Fierce Biotech
Jan 13th, 2025
JPM25: Regeneron, Illumina and more back Truveta for 10M genome sequencing project

To kick off the project, Regeneron made an upfront strategic investment of $119.5 million into Truveta, while Illumina chipped in $20 million as part of a series C financing.

Business Wire
Jan 11th, 2025
REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP announces that Regeneron Pharmaceuticals, Inc. investors with substantial losses have opportunity to lead Class Action lawsuit.

PR Newswire
Jan 8th, 2025
Nation'S Top 300 Teen Scientists Selected For Achievements In Stem Innovation And Leadership In Nation'S Oldest And Most Prestigious High School Competition

Regeneron Science Talent Search Sees Record Number of Applicants; $1.2 Million to be Awarded to Nation's Most Promising Young Scientists and Their SchoolsWASHINGTON, Jan. 8, 2025 /PRNewswire/ -- Society for Science (the Society) today announced the top 300 scholars in the Regeneron Science Talent Search 2025, the nation's oldest and most prestigious science and math competition for high school seniors. The 300 scholars will be awarded $2,000 each and their schools will be awarded $2,000 for each enrolled scholar.The Regeneron Science Talent Search scholars were selected from nearly 2,500 entrants from 795 high schools across 48 states, American Samoa, Guam, Washington, D.C., Puerto Rico and 14 other countries. US citizens living abroad are eligible to apply.Scholars were chosen based on their outstanding research, leadership skills, community involvement, commitment to academics, creativity in asking scientific questions and exceptional promise as STEM leaders demonstrated through the submission of their original, independent research projects, essays and recommendations. The 300 scholars hail from 200 American and international high schools in 33 states, Washington D.C., China, Hong Kong, Malaysia, and Switzerland.The full list of scholars can be viewed here: https://www.societyforscience.org/regeneron-sts/2025-scholars/"Congratulations to the 300 scholars in this year's Regeneron Science Talent Search," said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News. "With a record-breaking number of applications, these exceptional young scientists and engineers represent the best in the nation

Pharmaphorum
Jan 3rd, 2025
Regeneron builds in eye disease tech with Oxular takeover

Oxular is working on the development of novel drug/device combinations for sight-threatening retinal disorders, which is a key area of focus for Regeneron.

MarketBeat
Dec 1st, 2024
Erste Asset Management GmbH Makes New $42.48 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Erste Asset Management GmbH makes new $42.48 million investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

PharmiWeb
Nov 15th, 2024
Dupixent Sbla Accepted For Fda Review For The Treatment Of Chronic Spontaneous Urticaria

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is inadequately controlled by antihistaminesFDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decadeParis and Tarrytown, NY, November 15, 2024. The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment. The target action date for the FDA decision is April 18, 2025.The resubmitted sBLA is supported by data from the multi-study LIBERTY-CUPID phase 3 clinical program (Study A, Study B, and Study C) for Dupixent in CSU. The sBLA adds results from Study C, which was conducted in patients with uncontrolled CSU who were on standard-of-care antihistamines. Study C, the second LIBERTY-CUPID pivotal study in biologic-naïve patients, met its primary and key secondary endpoints, confirming results seen in the previous Study A. Results showed Dupixent significantly reduced itch and urticaria activity (itch and hives).Safety results in all LIBERTY-CUPID phase 3 studies were generally consistent with the known safety profile of Dupixent in its approved indications

PharmiWeb
Nov 11th, 2024
Astrazeneca And Amgen’S Tezspire Meets Both Co-Primary Endpoints In The Phase Iii Waypoint Trial In Patients With Chronic Rhinosinusitis With Nasal Polyps

Tezspire met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps. Tezspire demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo. Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that AstraZeneca and Amgen’s Tezspire (tezepelumab) demonstrated a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo